While orthopedic surgery, especially within the subset of spine surgery (although purists will consider spine surgery a discrete market rather than a subset of orthopedics), is characterized by higher than average revenue growth (by comparison to nearly all other medical device and related markets), growth is not uniformly positive on an absolute, let alone relative, basis.
Medtronic’s Infuse and its associated complications will be primarily responsible for an absolute decline in the spine surgery revenues for bone morphogenic proteins.
Concurrently, the spine surgery technology segment expected to have the biggest positive shift in share of the total spine surgery market is cervical artificial discs, which will generate a compound annual growth rate in sales of better than 16% through 2020.
The result of this is that these two segments — Bone Morphogenic Proteins and Cervical Artificial Discs — will have the biggest change in share of the total worldwide spine surgery market from 2011 to 2020.
Below is illustrated, for comparision sake, the significant shift in 2011 and 2020 revenues for these two segments.
Source: “Worldwide Spine Surgery: Products, Technologies, Markets and Opportunities 2010-2020”, Report #M520, MedMarket Diligence, LLC.